Under a newly signed partnership, AGC Pharma Chemicals and CatSci will combine to offer the former’s expertise in GMP manufacturing from development and manufacturing through to commercial with the latter’s in chemical development, analytical development, crystallisation and solid form, pre-formulation and HPAPI capabilities.

Japan’s AGC has announced plans for a new, 7,500 m² building at the site of its AGC Pharma Chemicals Europe CDMO operation in Spain. Costing about $100 million, this is scheduled to begin operation in 1H 2024 and will add 30% to the site’s capacity. This comes on top of a 30% increase in capacity announced in April 2020.